September/October 2016

This study explores the impact of a Medicare Part D formulary tier change, specifically with respect to branded insulin products, on insulin adherence, hemoglobin A1C, and diabetes-related events in elderly diabetic beneficiaries strategies for selection of appropriate and cost-effective therapy will also be discussed.

This study assesses comparative resource use for patients given a new diagnosis of nonvalvular atrial fibrillation treated with dabigatran or warfarin in a real-world setting.

This retrospective study compared the treatment patterns of ustekinumab with recommended maintenance administration every 12 weeks, with adalimumab and etanercept, administered weekly or every other week, for the treatment of plaque psoriasis.

This study presents the first information available regarding enablement and use by state and area characteristics of electronic prescribing of controlled substances by prescribers and pharmacy systems in from an e-prescribing network.

This manuscript addresses pharmacist understanding of and/or involvement with the Hospital-Acquired Condition Reduction Program (HACRP) at their institutions.

The role of Pharmacy and Therapeutic committees in formulary creations raises concerns.